Ernexa Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $582,000 | $68,000 | $0 | — |
| Gross profit | — | $486,000 | -$168,000 | $0 | — |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M |
| Operating expenses | $9.3M | $16.2M | $21.0M | $33.2M | $113.7M |
| Cost of revenue | — | $96,000 | $236,000 | $0 | — |
| Cash from operations | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M |
| Capital expenditure | $37,000 | $369,000 | $19,000 | $297,000 | $154,000 |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M | -$23.6M |
| Impairments | $33,000 | — | $0 | $0 | — |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M |
Shares outstanding 1.2M
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.